| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 03.03.2016 og
angivet som gældende fra 01.03.2016 (2981
dage). |
Ingen historik.
| Branche | | Fremstilling af farmaceutiske præparater (212000). |
| Sidst opdateret den 03.05.2016 og
angivet som gældende fra 28.04.2016 (2923
dage). |
| Historik | Start | Stop |
|---|
| Fremstilling af farmaceutiske præparater (212000) | 28.04.2016 | |
| Uoplyst (999999) | 01.03.2016 | 27.04.2016 |
| Revisionfravalgt | | false. |
| Sidst opdateret den 29.04.2016 og
angivet som gældende fra 28.04.2016 (2923
dage). |
| Historik | Start | Stop |
|---|
| false | 28.04.2016 | |
| true | 01.03.2016 | 27.04.2016 |
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Navne | | AKI Therapeutics A/S. |
| Sidst opdateret den 14.06.2022 og
angivet som gældende fra 31.05.2022 (699
dage). |
| Historik | Start | Stop |
|---|
| AKI Therapeutics A/S | 31.05.2022 | |
| AKI Therapeutics ApS | 13.09.2019 | 30.05.2022 |
| Renoguard ApS | 28.04.2016 | 12.09.2019 |
| ApS STM nr. 4310 | 01.03.2016 | 27.04.2016 |
| Tegningsregel | | Selskabet tegnes af en direktør og formanden for bestyrelsen i forening eller af den samlede bestyrelse. |
| Sidst opdateret den 06.07.2021 og
angivet som gældende fra 06.07.2021 (1028
dage). |
| Fortolkning
(2 tegningsmuligheder)
| | 1 direktør + formanden |
| bestyrelsen |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af en direktør og formanden for bestyrelsen i forening eller af den samlede bestyrelse | 06.07.2021 | |
| Selskabet tegnes af en direktør | 01.03.2016 | 05.07.2021 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:Grant Thornton Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:34209936
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):Basis for opinionWeconductedour audit in accordance with International Standards on Auditing (ISAs) and additional requirementsapplicable in Denmark. Our responsibilities under those standards and requirements are further described in thesection “Auditor’s responsibilities for the audit of the financial statements”. We are independent of the company inaccordance with International Ethical requirements for auditors (IESBA’s Code of Ethics), and the additionalrequirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with theserequirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriateto provide a basis for our opinion.
Konklusion (revision):OpinionWe have audited the financial statements of AKI Therapeutics for the financial year January 1 – December 31, 2022,which comprise statement of comprehensive income, statement of financial position, statement of changes in equity,cash flow statement, accounting policies and notes. The financial statements have been prepared in accordance withInternational Reporting Standards as endorsed by the EU and further requirements in the Danish Financial StatementsAct. In our opinion, the financial statements give a true and fair view of the financial position of the company at December31, 2022 and of the results of the company's operations and cash flows for the financial year January 1 – December31, 2022 in accordance with International Reporting Standards as issued by the International Accounting StandardsBoard (IASB) and adopted by the EU and additional requirements of the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on the management's reviewThe management is responsible for the management's Review. Our opinion on the financial statements døs not cover the management’s Review, and we do not express anyform of assurance conclusion thereon. In connection with our audit of the financial statements, it is our responsibility to read the Management´s Reviewand to consider whether the Management´s Review is materially inconsistent with the financial statements or theevidence obtained during the audit, or whether it otherwise appears to contain material misstatement. Furthermore, it is our responsibility to consider whether the Management´s Review provides the informationrequired under the Danish Financial Statements Act. Based on the work we have performed, we believe that Management´s Review is consistent with the financialstatements and that it has been prepared in accordance with the provisions of the Danish Financial Statement Act. We did not discover any material misstatement in the Management´s Review.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration